U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973421) titled 'Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer' on May 07.
Brief Summary: This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Platinum Resistant Ovarian Cancer
Intervention:
DRUG: U...